Partnered with Lilly, TVM Capital and Tillotts fund oral inflammatory bowel disease drug with up to $28M

Mage Bi­o­log­ics de­buted Thurs­day with a $28 mil­lion com­mit­ment from TVM Cap­i­tal Life Sci­ence and spe­cial­ty phar­ma com­pa­ny Tillotts Phar­ma.

The new biotech is cen­tered around a sin­gle as­set — a pre­clin­i­cal oral an­ti­body drug for in­flam­ma­to­ry dis­eases. Mage hopes to first test the drug can­di­date in ul­cer­a­tive col­i­tis, a form of in­flam­ma­to­ry bow­el dis­ease, and ex­pects to file to test it in clin­i­cal tri­als in 2024.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN